メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
大矢 由子
医学部・呼吸器内科学
h-index
1319
被引用数
21
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2015
2026
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(61)
類似のプロファイル
(6)
フィンガープリント
Yuko Oyaが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
89%
Epidermal Growth Factor Receptor
62%
Lung Cancer
57%
Osimertinib
33%
Cohort Study
27%
Chemotherapy
26%
Immune Checkpoint Inhibitor
26%
Pneumonia
25%
Progression Free Survival
24%
Anaplastic Lymphoma Kinase
24%
Adverse Event
19%
Crizotinib
18%
Retrospective Study
17%
Overall Survival
17%
Pembrolizumab
15%
Combination Therapy
14%
Programmed Cell Death
13%
Programmed Death 1 Ligand 1
13%
Protein Tyrosine Kinase Inhibitor
11%
Monotherapy
9%
Malignant Neoplasm
8%
Disease
7%
Nivolumab
7%
Alectinib
7%
Biological Marker
6%
Chemoradiation Therapy
6%
Xenon
6%
Malignant Pleura Effusion
6%
Quantum Dot
6%
Small Cell Lung Cancer
6%
Adenocarcinoma
6%
Bronchopleural Fistula
6%
Ceritinib
6%
Indocyanine Green
6%
Postoperative Complication
6%
Immunotherapy
6%
Fenbendazole
6%
Protein Mcl 1
6%
Cardiotoxicity
6%
Thyroid Cancer
6%
Trametinib
6%
Dabrafenib
6%
Anaplastic Thyroid Carcinoma
6%
Brain Metastasis
5%
Interstitial Lung Disease
5%
Neoplasm
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Lung Cancer
43%
Pneumonia
37%
Epidermal Growth Factor Receptor
27%
Lobectomy
20%
Retrospective Cohort Study
20%
Pembrolizumab
20%
Non-Small Cell Lung Cancer
19%
Osimertinib
19%
Overall Survival
18%
Durvalumab
18%
Immune Checkpoint Inhibitor
18%
Chemoradiotherapy
16%
Disease Free Survival
16%
Retrospective Study
16%
Progression Free Survival
14%
Adverse Event
13%
Programmed Death 1 Ligand 1
12%
Intensity Modulated Radiation Therapy
12%
Lung Adenocarcinoma
12%
Immunotherapy
11%
Surgery
11%
Hazard Ratio
10%
Neoplasm
8%
Segmentectomy
8%
Oncogene
8%
Disease
8%
Positron Emission Tomography-Computed Tomography
7%
Gene Mutation
7%
Cohort Analysis
7%
Diagnosis
6%
Clinical Stage
6%
Immune-Related Adverse Events
6%
Programmed Cell Death
6%
Long Term Survival
6%
Carcinoma
6%
Xenon
6%
Lung Function
6%
Lymph Node
6%
Bronchopleural Fistula
6%
Radiofrequency Ablation
6%
EGFR Inhibitors
6%
Lymph Node Metastasis
6%
Chest Tube
6%
Computer Assisted Tomography
6%
Malignant Pleural Effusion
6%
Mediastinal Germ Cell Tumor
6%
Lung Metastasis
6%
Indocyanine Green
6%
Gut Microbiome
6%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
45%
Osimertinib
21%
EGFR mutation
19%
Epidermal Growth Factor Receptor
18%
Overall Survival
14%
Clinical Outcomes
13%
Pneumonitis
12%
Elderly Patients
12%
Non-elderly
12%
Confidence Interval
12%
Immune Checkpoint Inhibitors
11%
Hazard Ratio
9%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
9%
Chemotherapy
8%
T790M mutation
8%
Immune Checkpoint Inhibitor Therapy
8%
Combination Therapy
8%
Risk Factors
7%
Lung Cancer
7%
Non-small Cell Lung Cancer Patients
7%
Elderly People
6%
ALK Rearrangement
6%
Total Lesion Glycolysis
6%
Spectrophotometry
6%
Fluorimetry
6%
Genomic Test
6%
Nanodrop
6%
Qubit
6%
Immune-related Adverse Events
6%
High Risk Histology
6%
Concurrent Chemotherapy
6%
Sublobar Resection
6%
Adverse Events
6%
IrAE
6%
Guideline Methodology
6%
Intensity-modulated Radiation Therapy
6%
Propensity Score Analysis
6%
Crimson
6%
Real-world Survey
6%
PD-1 Inhibitor
6%
ROS1 Rearrangement
6%
Small Cell Lung Cancer Transformation
6%
Stage IV NSCLC
6%
Corticosteroids
6%
Multicenter Retrospective Study
6%
Ceritinib
6%
EGFR T790M
6%
Retrospective Analysis
6%
Anaplastic Lymphoma Kinase Fusion
6%
Fusion Variants
6%
